Predictors of nadir serum creatinine after drainage of bilaterally obstructed kidneys due to different etiologies

Rabea Ahmed Gadelkareem1 · Ahmed Mahmoud Abdelraouf1 · Ahmed Mohammed El-Taher1 · Abdelfattah Ibrahim Ahmed1 · Nasreldin Mohammed1

Abstract

Purpose To identify the predictors of nadir serum creatinine (SCr) after drainage of bilaterally obstructed kidneys (BOKs) by different modes: double-J stent (JJ) versus percutaneous nephrostomy (PCN) and unilateral versus bilateral drainage.

Methods A prospective non-randomized study was performed on patients with BOKs and raised SCr during December 2019–November 2021. Relevant variables were studied for improvement and non-improvement and for benign and malignant underlying obstructions (BUO and MUO).

Results This study included 107 patients with BOKs including 68 (63.6%) males and 39 (36.4%) females. After drainage, 86 (80.4%) patients get improved, while 21 (19.6%) patients failed to reach a nadir SCr. Drainage by PCN was significantly higher in MUO, while JJ was significantly higher in BUO \((p<0.001)\). Also, bilateral drainage was a significant predictor of improvement in MUO \((p=0.03)\). In contrast, mode of drainage had no significant effect on improvement in BUO \((p=0.84)\), but bilateral drainage was a significant factor of rapid time to nadir \((p=0.02)\). Univariate analyses revealed no significant effects on the improvement in SCr from the studied variables, except the male gender \((p=0.01)\), old age \((p<0.001)\), MUO \((p=0.01)\), unilateral drainage \((p<0.001)\), and use of PCN for drainage \((p<0.001)\). By multivariate analysis, unilateral drainage \((p=0.01)\) and MUO \((p<0.001)\) were independent predictors of non-improvement in patients with BOKs.

Conclusions Male gender, old age, MUO, unilateral drainage, and drainage by PCN were significant predictors of non-improvement in SCr after drainage of BOKs. However, unilateral drainage and MUO were the only independent predictors of non-improvement.

Keywords Bilaterally obstructed kidneys · Double-J stent · Hydronephrosis · Percutaneous nephrostomy · Nadir serum creatinine

Introduction

The initial relief of obstruction in patients with bilaterally obstructed kidneys (BOKs) is the key point in the proper management and early normalization of renal functions. The underlying causes of obstruction are various between the benign and malignant pathologies [1, 2]. Also, the modalities of drainage have different modes regarding the route and laterality of drainage. All these factors result in variable outcomes, when normalization of the renal function is considered as the primary outcomes [2, 3]. This variability created a state of controversy and non-homogenous research designs that have failed to settle the debates in this subject [1]. On the other hand, the practical nature of this topic with individual experiences and preferences of choosing the mode of management warrants further studying. Regarding the endemism of the commonest underlying pathologies in our region, postrenal acute kidney injury (Po-AKI) due to BOKs puts this topic in a high priority in looking for an evidence-based recommendation for the best mode of drainage in the cases of BOKs [4–6]. We aimed to define the predictors of reaching nadir of the level of post-drainage serum creatinine (SCr) as the most common practical outcome of evaluation of the renal functions.
Methods

A prospective study was conducted at our hospital from December 2019 to November 2021. This study targeted patients with BOKs. It included patients with age > 18 years, BOKs due to benign or malignant ureteral obstructions (BUO and MUO), high serum creatinine > 2 mg/dl, and grades 1–3 hydronephrosis according the Onen grading system of hydronephrosis [7]. Exclusion criteria were vesicoureteral reflux, bleeding tendency, severe comorbidity preventing intervention, decompensated patients needing urgent dialysis until being compensated by conservation or dialysis, dialysis within 2 weeks from drainage of BOKs, and refusal of participation in the study.

The sample size was calculated using Epi Info version 7.1 for statistical calculation considering a power of the study, 80%, margin of error 10%, confidence level of 90%, and probability value 0.5. A sample size of 97 patients was estimated (the effect size was 0.21). However, considering the percentage of patients with lost to follow-up, we enrolled 110 patients. The number of patients who completed follow-up was 107 patients. This study was conducted in accordance with the principles of the Declaration of Helsinki and its amendments. This study was approved by the local ethical committee at our university, and institutional review board number is 17100860/2019. Also, it was registered in ClinicalTrials: NCT04077008.

In all patients, a full history was taken, including history of loin pain, fever, uremic manifestations as hiccough, vomiting, dyspepsia, anorexia, and urine output, comorbidity, medications, and surgical interventions. Also, systematic physical examination for body temperature, loin tenderness, scar of previous operations, and lower limb edema was done. Laboratory work ups included complete blood count, prothrombin concentration, SCr, blood urea nitrogen, blood gases, random blood sugar, and blood electrolytes. In all cases, imaging studies included ultrasonography, kidney-ureter-bladder radiography, and computed tomography. Magnetic resonance imaging was done only in 4 cases of MUO. Patients were counselled about the available methods of management, and consent for participation in the current study was obtained.

Patients were subjected to drainage of BOKs by Double-J stent (JJ) or percutaneous nephrostomy (PCN). Patients’ flowchart demonstrates their selection, allocation, and management (Fig. 1). Non-random allocation was due to the decision-making policy which was mostly delegated to the staff member on duty or the operator staff member in these emergency cases. The intraoperative and direct postoperative observations were carried out for vital signs, conscious level, and the amount and color of urine. Finally, patients were discharged with instructions of healthcare and follow-up.

The duration of follow-up of patients’ renal function was scheduled over 2 weeks, at 5th, 10th, and 14th day, postoperatively. At each visit, patients were evaluated by physical examination, urine output monitoring, checking PCN patency, SCr, and decompression of kidneys by ultrasonography.

The primary outcome of the study was defined as normalization of SCr or getting two consecutive readings of the lowest SCr value within 2 weeks after drainage of BOKs (nadir SCr level). The secondary outcome was the differences in improvement due to the underlying etiology of BOKs. Accordingly, patients were classified into those who reached a nadir SCr (improved group) and those who failed to reach a nadir SCr (not improved group). Normal SCr was defined as 0.7–1.2 mg/dL, and UOP was defined in different statuses as normal (> 400 ml/day), oliguria (100–400 ml/day), and anuria (< 100 ml/day). Grades of complications were defined according to the modified Clavien classification system [8].

Statistical analysis

Data were collected and analyzed using SPSS (Statistical Package for the Social Science, version 20, IBM, and Armonk, New York). Quantitative data were expressed as mean ± standard deviation (SD). Nominal data are given as number (n) and percentage (%) and compared using Chi-square. Distribution of continuous data was assessed with Shapiro–Wilk test, where normally distributed data were compared using Student t-test and not normally distributed data were compared using Mann–Whitney U test. In studying these data, patients were classified into 2 groups: improved and not improved according to pervious definitions of values. Predictors of non-improvement were determined by multivariate regression analysis. Level of confidence was kept at 95%, and hence, P value was considered significant if < 0.05.

Results

After exclusion of three patients who lost to follow-up, the current study included 107 patients who had drainage of BOKs. Improved group included 86 (80.4%) patients, while not improved group included 21 (19.6%) patients. The characteristics of patients and the effects of different variables on the primary outcome are demonstrated at different classifications, either according to the improvement in SCr or the underlying etiology (Tables 1, 2, 3, 4, 5, 6, 7).

The current study included 68 (63.6%) males and 39 (36.4%) females. Totally, the mean age was 56.56 ± 13.8 years and the mean BMI was 25.28 ± 5.5 kg/m².

 Springer
The characteristics of the patients relative to their grouping into BUO and MUO are summarized in Table 5.

BUO was the underlying cause in 53 (49.5%) patients, including urolithiasis in 43 (40%), ureteral stricture in 6 (5.6%), iatrogenic ureteral injury in 2 (1.9%), and retroperitoneal fibrosis in 2 (1.9%) patients. However, MUO occurred in 54 (50.5%) patients, including urinary bladder cancer in 30 (28%), prostate cancer in 5 (4.7%), cervical cancer in 6 (5.6%), colorectal cancer in 11 (10.3%), and lymphoma in 2 (1.9%) patients.

The total mean SCr at presentation was $6.13 \pm 3.2$ mg/dl. There were no statistically significant differences between both groups in the preoperative laboratory and imaging variables (Table 2). The underlying pathology of ureteral obstruction was differentiated into BUO and MUO...
with subcategories. They showed significant differences in their effects on the improvement in SCr level (Table 3).

Regarding the mode of drainage of BOKs (Tables 4, 5, 6), 57% of patients in the improved group underwent bilateral drainage, while the majority (81%) of patients in the not improved group underwent unilateral drainage. Also, with the exception of 2 patients, all those patients who did not improve had PCN (Table 4). The majority of the patients with BUO were managed by JJ, while most of patients with MUO were managed by PCN ($P < 0.001$) (Tables 5 and 6).

Table 1 Demographic and preoperative clinical characteristics of patients in the improved ($n = 86$) and not improved ($n = 21$) groups (total $n = 107$)

| Characteristics                              | Improved ($n = 86$) | Not improved ($n = 21$) | $P$ value |
|----------------------------------------------|--------------------|------------------------|-----------|
| Age (years)                                  | 53.95 ± 13.18      | 67.23 ± 10.86          | $< 0.001$ |
| Gender                                       |                    |                        |           |
| Male                                         | 50 (58.1%)         | 18 (85.7%)             | 0.01      |
| Female                                       | 36 (41.9%)         | 3 (14.3%)              |           |
| BMI (kg/m$^2$)                               | 25.53 ± 5.55       | 24.25 ± 5.31           | 0.34      |
| Comorbidity                                  |                    |                        |           |
| Diabetes mellitus                            | 21 (24.4%)         | 3 (14.3%)              | 0.24      |
| Hypertension                                 | 17 (19.8%)         | 5 (23.8%)              | 0.44      |
| Cardiac diseases                             | 6 (7%)             | 2 (9.5%)               | 0.49      |
| Pulmonary diseases                           | 0                  | 1 (4.8%)               | 0.19      |
| Smoking                                      | 12 (14%)           | 5 (23.8%)              | 0.21      |
| Previous surgical interventions              |                    |                        |           |
| Open kidney surgery                          | 1 (1.2%)           | 0                      | 0.80      |
| PCN                                          | 2 (2.3%)           | 1 (4.8%)               | 0.48      |
| Renal SWL                                     | 3 (3.5%)           | 0                      | 0.51      |
| Open urethral surgery                        | 3 (3.5%)           | 0                      | 0.51      |
| URS                                          | 1 (1.2%)           | 0                      | 0.80      |
| Double-J stent                               | 3 (3.5%)           | 0                      | 0.51      |
| Loin pain                                    |                    |                        |           |
| Unilateral                                   | 5 (5.8%)           | 0                      | 0.21      |
| Bilateral                                    | 41 (47.7%)         | 14 (66.7%)             |           |
| None                                         | 40 (46.5%)         | 7 (33.3%)              |           |
| Urine output at presentation                 |                    |                        |           |
| Normal                                       | 34 (39.5%)         | 12 (57.1%)             | 0.20      |
| Oliguria                                     | 28 (32.6%)         | 6 (28.6%)              |           |
| Anuria                                       | 24 (27.9%)         | 3 (14.3%)              |           |
| Uremic manifestations                        |                    |                        |           |
| Hiccough                                     | 8 (9.3%)           | 2 (9.5%)               | 0.62      |
| Vomiting                                     | 12 (14%)           | 1 (4.8%)               | 0.22      |
| None                                         | 74 (87.1%)         | 19 (90.5%)             | 0.50      |
| Temperature ($°C$)                            | 37.19 ± 0.51       | 37.36 ± 0.61           | 0.18      |
| Loin tenderness                              |                    |                        |           |
| Unilateral                                   | 3 (3.5%)           | 1 (4.8%)               | 0.41      |
| Bilateral                                    | 8 (9.3%)           | 4 (19%)                |           |
| None                                         | 75 (87.2%)         | 16 (76.2%)             |           |
| Pre-drainage dialysis sessions               |                    |                        |           |
| None                                         | 75 (87.2%)         | 19 (90.5%)             | 0.68      |
| Once                                         | 3 (3.5%)           | 0                      |           |
| Twice and more                               | 8 (9.3%)           | 2 (9.5%)               |           |
| Underlying obstruction nature                |                    |                        |           |
| Malignant ureteral obstruction               | 36 (41.9%)         | 18 (85.7%)             | $< 0.001$ |
| Benign ureteral obstruction                  | 50 (58.1%)         | 3 (14.3%)              |           |

BMI body mass index, PCN percutaneous nephrostomy, SWL extracorporeal shockwave lithotripsy, URS: ureteroscopy
The mean SCr at 5th, 10th, and 14th day of follow-up was $3 \pm 2.2, 1.8 \pm 1.4,$ and $1.49 \pm 1.19.$ The mean nadir SCr in the improvement group was $1.13 \pm 0.88$ mg/dl. The mean SCr in patients with normalized SCr and in patients who reached an abnormal nadir SCr was $0.7 \pm 0.3$ mg/dl and $2.9 \pm 1.2$ mg/dl. The differences between the mean SCr at presentation and at the lowest post-drainage level were compared between both groups. Also, these values were compared between BUO and MUO groups (Fig. 2).

The mean of the total time-to-nadir SCr was insignificantly different ($P = 0.17$) between the unilateral ($9.11 \pm 4.01$ days) and bilateral ($7.88 \pm 4.11$ days) drainage. In BUO, however, the mean time-to-nadir SCr was significantly longer ($P = 0.02$) in the unilateral drainage ($10 \pm 3.97$ days) than it in the bilateral drainage ($7.37 \pm 3.87$ days).

By multivariate analysis, the independent predictors of non-improvement were only MUO ($p < 0.001$) and unilateral drainage ($p = 0.01$) (Table 7).

Regarding the complications, there were 2 cases that were converted to PCN after failure of JJ insertion (Grade 1). Also, 1 patient had failed PCN placement and converted to JJ (Grade 3a). Postoperative hematuria occurred in 5 (14%) patients of JJ group and 9 (12.5%) patients in PCN group (Grade 2). All those cases were treated conservatively without blood transfusion. At follow-up visits, 17 patients complained of irritative lower urinary tract symptoms after

### Table 2 Effects of the preoperative laboratory and imaging characteristics on the primary outcome in all patients

| Characteristics                              | Improved ($n = 86$) Mean ± SD | Not improved ($n = 21$) Mean ± SD | $P$ value |
|----------------------------------------------|-------------------------------|-----------------------------------|-----------|
| Parenchymal thickness (cm$^3$)               |                               |                                   |           |
| Right kidney                                 | 13.17 ± 2.44                  | 12.86 ± 2.45                      | 0.59      |
| Left kidney                                  | 12.73 ± 2.41                  | 13.23 ± 2.34                      | 0.38      |
| Renal length (cm)                            |                               |                                   |           |
| Right kidney                                 | 11.91 ± 1.52                  | 11.02 ± 1.29                      | 0.15      |
| Left kidney                                  | 11.74 ± 1.62                  | 11.48 ± 1.37                      | 0.50      |
| Serum creatinine (mg/dl)                     | 5.90 ± 3.07                   | 7.06 ± 3.59                       | 0.13      |
| Random blood sugar (mg/dl)                   | 127.45 ± 49.60                | 134.81 ± 88.42                    | 0.61      |
| pH                                           | 7.35 ± 0.07                   | 7.35 ± 0.08                       | 0.91      |
| CO$_2$                                       | 25.35 ± 6.19                  | 22.80 ± 4.91                      | 0.08      |
| Acid–base deficit (mmol/l)                   | -8.48 ± 5.55                  | -9.79 ± 5.34                      | 0.33      |
| HCO$_3^+$                                    | 15.44 ± 4.25                  | 14.71 ± 3.32                      | 0.46      |
| Leucocytes (cells × 10$^3$/ul)               | 8.23 ± 2.96                   | 9.40 ± 3.99                       | 0.13      |
| Hemoglobin (gm/dl)                           | 10.98 ± 1.61                  | 10.73 ± 1.35                      | 0.49      |
| Pyuria (cells/HPF)$^a$                       | 42.44 ± 35.14                 | 42.09 ± 35.99                     | 0.96      |

$^a$Performed only for patients with urine output allowed sampling.

### Table 3 Effect of the nature of the underlying obstruction on the primary outcome in all patients

| Underlying obstruction                        | Improved ($n = 86$) | Not improved ($n = 21$) | $P$ value |
|-----------------------------------------------|---------------------|-------------------------|-----------|
| Benign ureteral obstruction                   |                     |                         | 0.01      |
| Urolithiasis                                  | 39 (45.3%)          | 4 (19.1%)               |           |
| Ureteral stricture                            | 6 (6.9%)            | 0                       |           |
| Iatrogenic ureteric injury                    | 2 (2.3%)            | 0                       |           |
| Retroperitoneal fibrosis                      | 2 (2.3%)            | 0                       |           |
| Malignant ureteral obstruction                |                     |                         |           |
| Urinary bladder cancer                        | 17 (19.8%)          | 13 (61.9%)              |           |
| Cancer prostate                               | 3 (3.4%)            | 2 (14.3%)               |           |
| Cervical cancer                               | 5 (5.8%)            | 1 (4.8%)                |           |
| Cancer colon                                  | 5 (5.8%)            | 1 (4.8%)                |           |
| Cancer rectum                                 | 5 (5.8%)            | 0                       |           |
| Lymphoma                                      | 2 (2.3%)            | 0                       |           |
by Cordeiro et al. [11] and Haas et al. [12]. The latter conducted the largest study in the literature on 238,500 cases of MUO [12]. They reported bladder cancer (23%) and prostate cancer (17.9%) as the most common causes of MUO. In contrast, Kanou et al. [13] and Aekgawong et al. [14] found that the extra-urological malignancies such as cervical cancer are more common than the other variants of obstructing malignancies. However, many studies reported that genitourinary malignancies represent more than 25% of MUO causes [15–17].

On average, the preoperative SCr was 6.13 ± 3.2 mg/dl. It had no statistically significant effect the improvement in SCr which was similar to the results [18–20]. However, it was different from the previous results found that the low SCr at presentation was a statistically significant predictor for recoverability of renal functions in patients with Po-AKI [5, 14, 21].

BUO may have criteria different from MUO. They may allow passing a ureteral stent through the ureter. Also, the curable nature may promote the urologist to try all the efforts to keep the normal passage. Moreover, patients with BUO such as that due to urolithiasis usually have no systematic dysfunctions. Accordingly, they have intact physiological and metabolic compensatory responses or mechanisms. The latter processes are usually reflected on the patient’s physical conditions, functional performance, and they can competently compensate for the pathophysiological sequels of AKI after drainage. These functional competences may help making a decision of invasive interventions such as JJ placement [1, 6, 18, 19]. This is in contrast with patients with MUO who have bad general performance and short life expectancy due to the advanced malignancy [20, 22].

MUO has two main mechanisms for development of AKI. Firstly, it causes mechanical obstruction of the ureters like any other cause hindering the urine flow. Secondly, it has its own metabolic insults that affect the whole body environment and the concomitant burden of medications such as chemotherapy [2].

According to the current study, bilateral drainage of BOKs has a statistically significant effect on the recovery of renal function. It could significantly increase the possibility of renal function recovery in MUO. Also, it could significantly make the time-to-nadir SCr shorter in BUO. Similarly, many studies reported a significant effect of bilateral drainage on the recovery of renal functions [14, 23].

Although urologists meet with the cases of BOKs mandating drainage, there are no guidelines addressing the recommendation to the preferences of laterality of drainage [2, 24]. In our study, nadir SCr was 1.13 ± 0.88 mg/dl with a significantly longer time to nadir in cases of unilateral drainage than that in bilateral drainage of BOKs. Also, we found that time-to-nadir SCr in patients with BUO and bilateral drainage was significantly lower than that with unilateral drainage (P < 0.02). In contrast, some studies found no significant

---

**Table 4** Effect of the mode of drainage on the primary outcome in all patients

| Variables            | Improved (n = 86) | Not improved (n = 21) | P value  |
|----------------------|------------------|-----------------------|----------|
| Mode of drainage     |                  |                       | <0.001   |
| Unilateral PCN       | 28 (32.5%)       | 17 (81%)              |          |
| Bilateral PCN        | 22 (25.6%)       | 2 (9.5%)              |          |
| Unilateral JJ        | 9 (10.5%)        | 0                     |          |
| Bilateral JJ         | 24 (27.9%)       | 2 (9.5%)              |          |
| PCN/JJ               | 3 (3.5%)         | 0                     |          |
| Laterality of drainage|                |                       | <0.001  |
| Unilateral drainage  | 37 (43%)         | 17 (81%)              |          |
| Bilateral drainage   | 49 (57%)         | 4 (19%)               |          |
| Type of catheter*    |                  |                       | <0.001   |
| JJ                   | 33 (39.8%)       | 2 (9.5%)              |          |
| PCN                  | 50 (60.2%)       | 19 (90.5%)            |          |

* JJ double-J stent, PCN percutaneous nephrostomy

The three patients who underwent double-J on one side and percutaneous nephrostomy (PCN) on the other side weren’t included in comparison of type of catheter

JJ placement (Grade 2). PCN slippage occurred only in one patient, where it was repositioned within 3 h.

**Discussion**

BOKs is a classic form of acute kidney injury that could be cured by resolution of the obstructing factor. Drainage can be achieved by placement of PCN or JJ until stabilization of the renal functions and arrangement for the primary treatment. Stabilization of renal function is usually monitored by the decrease in the level of SCr. Many factors may predict the recoverability of renal function, including the tool and laterality of drainage. These predictors have been variably studied without reaching a consensus on the optimal strategy of drainage of BOKs [1, 9]. Here, we conducted this prospective study considering the nadir SCr as the primary outcome.

Overall, the most common cause of obstruction in the current study was urolithiasis (40%). This was consistent with the data reported in most of the literature, regarding urolithiasis as the most common cause of ureteric obstruction in Po-AKI. This includes studies from our locality that reported urolithiasis as the main cause of obstruction [1, 5, 6, 10].

In our study, urological malignancies represented 65% of MUO, where bladder cancer was the most common cause (55.6%). These results were similar to those in the studies by Cordeiro et al. [11] and Haas et al. [12]. The latter
## Table 5 Differences in demographic and clinical characteristics of groups of patients with benign and malignant ureteral obstructions

| Variables                              | Benign ureteral obstruction (n = 53) | Malignant ureteral obstruction (n = 54) | P value |
|----------------------------------------|--------------------------------------|----------------------------------------|---------|
| Age (year)                             | Mean ± SD/frequency (percentage)     |                                        |         |
| Gender                                 |                                      |                                        |         |
| Male                                   | 31 (58.5%)                           | 37 (68.5%)                             | 0.381   |
| Female                                 | 22 (41.5%)                           | 17 (31.5%)                             |         |
| Height (m)                             | 1.66 ± 0.06                          | 1.64 ± 0.07                            | 0.120   |
| Weight (kg)                            | 72.2 ± 16.9                          | 66.9 ± 19                              | 0.066   |
| BMI (kg/m²)                            | 26 ± 5.3                             | 24.5 ± 5.4                             | 0.091   |
| Comorbidities                          |                                      |                                        |         |
| Diabetes mellitus                      | 10 (18.9%)                           | 14 (25.9%)                             | 0.458   |
| Hypertension                           | 10 (18.9%)                           | 12 (22.2%)                             |         |
| Cardiac diseases                       | 3 (5.7%)                             | 5 (9.3%)                               |         |
| Pulmonary diseases                     | 1 (1.9%)                             | 0 (0%)                                 |         |
| None                                   | 29 (54.7%)                           | 23 (42.6%)                             |         |
| Previous surgical interventions        | 8 (15.1%)                            | 6 (11.1%)                              | 0.932   |
| Smoking                                | 9 (17%)                              | 8 (14.8%)                              | 0.775   |
| Pain laterality                        |                                      |                                        |         |
| Right                                  | 0 (0%)                               | 3 (5.6%)                               | 0.067   |
| Left                                   | 1 (1.9%)                             | 1 (1.9%)                               |         |
| Bilateral                              | 34 (64.1%)                           | 21 (38.9%)                             |         |
| None                                   | 18 (34%)                             | 29 (53.7%)                             |         |
| Temperature (°C)                       | 37.2 ± 0.5                           | 37.3 ± 0.6                             | 0.273   |
| UOP at presentation                    |                                      |                                        |         |
| Normal                                 | 13 (24.5%)                           | 33 (61.1%)                             | < 0.001 |
| Oliguria                               | 21 (39.6%)                           | 13 (24.1%)                             |         |
| Anuria                                 | 19 (35.9%)                           | 8 (14.8%)                              |         |
| Loin tenderness                        |                                      |                                        |         |
| Unilateral                             | 1 (1.9%)                             | 3 (5.6%)                               | 0.753   |
| Bilateral                              | 5 (9.4%)                             | 7 (13%)                                |         |
| None                                   | 47 (88.7%)                           | 44 (81.5%)                             |         |
| Pre-drainage dialysis                  |                                      |                                        |         |
| Yes                                    | 5 (9.4%)                             | 8 (14.8%)                              | 0.852   |
| None                                   | 48 (90.6%)                           | 46 (85.2%)                             |         |
| Uremic symptoms                        |                                      |                                        |         |
| Yes                                    | 10 (13.2%)                           | 13 (24.1%)                             | 0.668   |
| None                                   | 43 (81.1%)                           | 44 (81.5%)                             |         |
| Mean parenchymal thickness of drained unit(s) (mm) | 13.4 ± 2.3                           | 12.8 ± 2.3                             | 0.151   |
| SCr at presentation (mg/dl)            | 6.2 ± 2.9                             | 6.1 ± 3.5                              | 0.501   |
| eGFR at presentation (ml/min/1.73 m²)   | 12.8 ± 9.5                            | 13.1 ± 8.1                             | 0.510   |
| Random blood sugar (mg/dl)             | 128.4 ± 53.2                         | 129.5 ± 64.3                           | 0.519   |
| pH                                     | 7.35 ± 0.07                           | 7.36 ± 0.08                            | 0.615   |
| PCO₂ (mmHg)                            | 25.7 ± 5.4                            | 24 ± 6.5                               | 0.125   |
| Acid–base deficit (mmol/l)             | − 9.1 ± 5.1                           | − 8.4 ± 5.9                            | 0.549   |
| HCO₃ (mmol/l)                          | 15.1 ± 4.1                            | 15.5 ± 4.1                             | 0.570   |
| Leucocytes (Cells × 10⁷/ul)            | 8.7 ± 3.3                             | 8.2 ± 3.1                              | 0.408   |
| Hemoglobin (gm/dl)                     | 10.9 ± 1.7                            | 11 ± 1.4                               | 0.861   |
effect of drainage laterality on reaching a nadir SCr and reported a time-to-nadir SCr of 7.7–10 days \[18, 24\]. However, most of these studies did not exclude patients with severe hydronephrosis. It is important to exclude patients with non-functioning or poorly functioning kidneys, when laterality is compared.

In our study, MUO was an independent predictive factor for non-improvement after successful drainage. This

Table 5 (continued)

| Variables | Benign ureteral obstruction \((n = 53)\) | Malignant ureteral obstruction \((n = 54)\) | \(P\) value |
|-----------|--------------------------------|--------------------------------|------------|
| Mode of drainage | Mean ± SD/frequency (percentage) | | |
| Unilateral PCN | 12 (22.6%) | 33 (61.1%) | <0.001 |
| Bilateral PCN | 6 (11.3%) | 18 (33.3%) | |
| Unilateral JJ | 9 (17%) | 0 (0%) | |
| Bilateral JJ stent | 25 (47.2%) | 1 (1.9%) | |
| PCN/JJ stent | 1 (1.9%) | 2 (3.7%) | |
| Post-drainage mean UOP (ml) | 2230 ± 940 | 2050 ± 650 | 0.554 |
| Post-drainage mean weight (kg) | 71.6 ± 16.8 | 66.5 ± 18.7 | 0.070 |

Post-drainage kidney function

| SCr at 5th day (mg/dl) | 2.8 ± 2.1 | 3.3 ± 2.3 | 0.172 |
| SCr at 10th day (mg/dl) | 2 ± 1.8 | 2.6 ± 2 | 0.08 |
| SCr at 14th day (mg/dl) | 1.3 ± 1.3 | 1.7 ± 1.1 | 0.007 |
| eGFR at lowest SCr level (ml/min/1.73 m²) | 85 ± 41.2 | 63.4 ± 38.8 | 0.010 |

Table 6 Effect of modes of drainage per the underlying obstruction on the primary outcome

| Modes of drainage per category of underlying ureteral obstruction | Frequency per outcome groups | \(P\) value |
|---|---|---|
| **Malignant ureteral obstruction** | | |
| **Mode of drainage** | Improved \((n = 36)\) | Not improved \((n = 18)\) | 0.03 |
| Unilateral PCN | 17 (47.2%) | 16 (88.9%) | |
| Bilateral PCN | 16 (44.4%) | 2 (11.1%) | |
| Bilateral JJ | 1 (2.8%) | 0 | |
| PCN/JJ | 2 (5.6%) | 0 | |
| **Laterality of drainage** | | 0.03 |
| Bilateral drainage | 19 (52.7%) | 2 (11.1%) | |
| Unilateral drainage | 17 (47%) | 18 (88.9%) | |
| **Benign ureteral obstruction** | | |
| **Mode of drainage** | Improved \((n = 50)\) | Not improved \((n = 3)\) | 0.84 |
| Unilateral PCN | 11 (22%) | 1 (33.3%) | |
| Bilateral PCN | 6 (12%) | 0 | |
| Unilateral JJ | 9 (18%) | 0 | |
| Bilateral JJ | 23 (46%) | 2 (66.7%) | |
| PCN/JJ | 1 (2%) | 0 | |
| **Laterality of drainage** | | 0.49 |
| Bilateral drainage | 30 (60%) | 2 (66.7%) | |
| Unilateral drainage | 20 (40%) | 1 (33.3%) | |

**BMI** body mass index, **CI** confidence interval, **eGFR** estimated glomerular filtration rate, **HCO3** bicarbonate, **JJ** double-J stent, **PCN** percutaneous nephrostomy, **PCO2** blood carbon dioxide, **pH** potential hydrogen describing the acidity or basicity of blood, **SCr** serum creatinine, **SD** standard deviation, **UOP** urine output

*In the group of malignant ureteral obstruction, only 6 patients had a history of chemotherapy regimen*
was consistent with many studies in the literature [11, 22, 25]. Moreover, other studies reported that improved patients with MUO would need longer time-to-improve up to > 15 days [16, 26], which was comparable to our results. The current results showed that the rate of improvement in SCr after drainage by JJ was significantly higher than it after drainage by PCN. This finding was inconsistent with many previous studies that found no difference between both of these methods of drainage [5, 27]. This could be attributed to the preference to use PCN in cases of MUO in our hospital, where this association might be the reason that why it lost the statistical significance after incorporation in multivariate analysis. On the other hand, JJ may have lower success rates and higher rates of complications in MUO [28].

The previous studies reported many independent factors of recovery of renal functions after drainage of BOKs such as symptom duration of < 25 days, the patient’s age, and low platelet count and serum albumin at presentation [1, 2, 5, 14, 19]. In parallel, MUO and unilateral drainage were independent predictors in our results. However, patients in these studies were different from ours; they had Po-AKI in patients with only-functioning kidneys due to BUO only such as urolithiasis or MUO only [2, 5, 14, 19, 29].

The limitations of the current study included the non-random allocation of patients in receiving the mode of drainage. Hence, the sufficiency of the current results for drawing a very solid evidence could be criticized due to a proposed bias in patient selection for a certain mode of drainage by the operator. Also, the scope of this study did not withstand studying quality of life, patients’ survival [30], and whether the effect of normalization of SCr enabled those patients to catch earlier dates for correction of the underlying causes. Furthermore, reliable recording of the daily changes in UOP and body weight was not amenable after discharging the patients from the hospital within 1–2 days. Besides, generalizability of the results might be limited as the study was single-center one. However, the cumulative evidence in the literature may alleviate these limitations.

### Conclusions

BOKs had various underlying etiologies, including urolithiasis as the most common benign cause and bladder cancer as the most common malignant cause. Old males were more affected rather than females. There were numerous modes of drainage of BOKs, regarding the type of catheter and the laterality of drainage. The univariate analyses showed that the predictive factors for non-improvement in renal function represented by SCr level after drainage of BOKs included the male gender, old age, MUO, unilateral drainage, and use of PCN for drainage. By multivariate analysis, however, unilateral drainage and MUO were the only independent predictors of non-improvement after drainage of BOKs. Bilateral drainage was superior to unilateral drainage in the reduction in SCr level to a nadir. Time-to-nadir SCr was significantly shorter in BUO than in MUO.

### Table 7: Multivariate regression analysis of the predictors of non-improvement in serum creatinine after drainage in patients with bilaterally obstructed kidneys

| Variables                              | Odds ratio | 95% CI       | P value |
|----------------------------------------|------------|--------------|---------|
| Age > 60 years                          | 3.19       | 0.82–12.43   | 0.09    |
| Male gender                            | 4.30       | 0.92–17.77   | 0.06    |
| Malignant ureteral obstruction          | 11.23      | 1.62–22.87   | < 0.001 |
| Double-J stent                          | 0.27       | 0.25–2.97    | 0.28    |
| Unilateral drainage                     | 5.88       | 1.53–11.76   | 0.01    |

*P value was significant if < 0.05  
CI confidence interval*
Fig. 2 Graphical representations of the pre- and post-drainage values of renal functions. It shows the differences between the mean serum creatinine (SCr) levels (A and B) and the estimated glomerular filtration rate (eGFR) (C), at presentation and at nadir SCr levels for different groups of patients. Between the improved and not improved groups, the values of Cohen’s $d$, Glass’s delta, and Hedges’ $g$ tests for mean SCr at presentation/nadir levels were 0.36/1.49, 0.39/1.36, and 0.37/1.59, respectively. However, between the benign and malignant ureteral obstruction (BUO and MUO) groups, the effect size values of Cohen’s $d$, Glass’s delta, and Hedges’ $g$ for mean SCr at presentation/nadir levels were 0.03/0.33, 0.03/0.31, and 0.03/0.33, respectively. Also, the corresponding values for mean eGFR in BUO and MUO groups were 0.03/0.54, 0.03/0.52, and 0.03/0.54, respectively.
Acknowledgements There is no specified fund for this study.

Author contributions RAG contributed in concept design, data collection, statistical analysis, writing, and approval; AMA contributed in data collection, statistical analysis, writing, and approval; AME-T contributed in concept design, writing, revision, and approval; NM contributed in data collection, writing, revision, and approval.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Declarations

Conflict of interests The authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Weltings S, Schout BMA, Roshani H, Kamphaus GM, Pelger RCM (2019) Lessons from literature: nephrostomy versus double J ureteral catheterization in patients with obstructive urolithiasis: which method is superior? J Endourol 33:777–786. https://doi.org/10.1089/end.2019.0309

2. New FJ, Deverill SJ, Somani BK (2021) Outcomes related to percutaneous nephrostomies (PCN) in malignancy-associated ureteric obstruction: a systematic review of the literature. J Clin Med 10:2354. https://doi.org/10.3390/jcm10112354

3. Halarnkar RG, Prabhudesai MR, Mandrekar PTN, Chari PD, Dessai G, Talwadker NB (2020) Factors predicting outcome in patients with obstructive anuria. IOSR J 19:32–35. https://doi.org/10.9790/0853-1909023235

4. Zarzour AH, Selim M, Abd-Elseayed AA, Hameed DA, Abdelaziz MA (2008) Muscle invasive bladder cancer in Upper Egypt: the shift in risk factors and tumor characteristics. BMC Cancer 8:250. https://doi.org/10.1186/1471-2407-8-250

5. Harraz AM, Zahran MH, Nabeeh H, Atwa AM, Melilka KN, Orban H et al (2018) Mp89-05 percutaneous nephrostomy tube and double J stent for relief of benign obstructive uropathy: a case-control study. J Urol 199:e1207–e1207. https://doi.org/10.1016/j.juro.2018.02.2945

6. Elbatanouny AM, Ragheb AM, Abdelbary AM, Fathy H, Masoud AM, Abd El Latif A et al (2020) Percutaneous nephrostomy versus JJ ureteric stent as the initial drainage method in kidney stone patients presenting with acute kidney injury: a prospective randomized study. Int J Urol 27:916–921. https://doi.org/10.1111/iju.14331

7. Onen A (2020) Grading of hydronephrosis: an ongoing challenge. Front Pediatr 8:458. https://doi.org/10.3390/fped.2020.00458

8. Kumar S, Dutt UK, Singh S, Dorairajan LN, Srerag KS, Zaphu T, Manikandan R (2020) Prospective audit of complications after ultrasonography-guided percutaneous nephrostomy for upper urinary tract obstruction using modified Clavien classification system. Urol Ann 12:31–36. https://doi.org/10.4103/UAA.UA_18_19

9. Tibana TK, Grubert RM, Santos RFT, Fornazari VAV, Domingos AA, Reis WT et al (2019) Percutaneous nephrostomy versus antegrade double-J stent placement in the treatment of malignant obstructive uropathy: a cost-effectiveness analysis from the perspective of the Brazilian public health care system. Radiat Bras 52:305–311. https://doi.org/10.1590/0100-3984.2018.0127

10. Ghaffar A, Ahmed R (2007) JJ-stenting: efficacy in the management of obstructive uropathy. Med Forum Mon 14:56–59

11. Cordeiro MD, Coelho RF, Chade DC, Pessoa RR, Chab M, Colombo-Júnior JR et al (2016) A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int 117:266–271. https://doi.org/10.1111/bju.12963

12. Haas CR, Shah O, Hyams ES (2020) Temporal trends and practice patterns for inpatient management of malignant extrinsic ureteral obstruction in the United States. J Endourol 34:828–835. https://doi.org/10.1089/end.2020.0053

13. Kanou T, Fujiyama C, Nishimura K, Tokuda Y, Uozumi J, Masaki Z (2007) Management of extrinsic malignant ureteral obstruction with urinary diversion. Int J Urol 14:689–692. https://doi.org/10.1111/j.1442-2042.2007.01747.x

14. Aekgawong S, Ramart P (2021) Predicting factors for improvement of serum creatinine after percutaneous nephrostomy in adults with bilateral hydronephrosis associated with malignancy. Insight Urol 42:1–6. https://doi.org/10.52786/issn.a.15

15. Little B, Ho KJ, Gawley S, Young M (2003) Use of nephrostomy tubes in ureteric obstruction from incurable malignancy. Int J Clin Pract 57:180–181

16. Liatsikos EN, Karnabatidis D, Katsanos K, Kalilidonis P, Kat sakiori P, Kagadis GC et al (2009) Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol 182:2613–2617. https://doi.org/10.1016/j.juro.2009.08.040

17. Chioo RK, Chang WY, Horan JI (1990) Ureteral obstruction associated with prostate cancer: the outcome after percutaneous nephrostomy. J Urol 143:957–959. https://doi.org/10.1016/s0022-5347(17)30150-9

18. Pappas P, Stravodimos KG, Mitropoulos D, Kontopoulou C, Har moglis S, Giannopoulou M et al (2000) Role of percutaneous urinary diversion in malignant and benign obstructive urethropy. J Endourol 14:401–405. https://doi.org/10.1089/end.2000.14.401

19. Rajadoss MP, Berry CJ, Rebekah GJ, Moses V, Keshava SN, Jacob KS et al (2016) Predictors of renal recovery in renal failure secondary to bilateral obstructive urolithiasis. Arab J Urol 14:269–274. https://doi.org/10.1016/j.aju.2016.08.001

20. Garg G, Bansal N, Singh M, Sankhwar SN (2019) Role of percutaneous nephrostomy in bladder carcinoma with obstructive uropathy: a story revisited. Indian J Palliat Care 25:53–56. https://doi.org/10.4103/IJPC.IJPC_102_18

21. Sharma U, Yadav SS, Tomar V (2015) Factors influencing recoverability of renal function after urinary diversion through percutaneous nephrostomy. Urol Ann 7:499–503. https://doi.org/10.4103/0974-7796.157960

22. Radecka E, Magnusson M, Magnusson A (2006) Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. Acta Radiol 47:328–331. https://doi.org/10.1080/02841850500492092
23. Hyppolite JC, Daniels ID, Friedman EA (1995) Obstructive uropathy in gynecologic malignancy. Detrimental effect of intraureteral stent placement and value of percutaneous nephrostomy. ASAIO J 41:M318–M323
24. Nariculam J, Murphy DG, Jenner C, Sellar N, Gwyther S, Gordon SG et al (2009) Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol 82:571–576. https://doi.org/10.1259/bjr/38306763
25. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT (2011) Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med 22:399–406. https://doi.org/10.1016/j.ejim.2011.05.005
26. Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87:21–24. https://doi.org/10.1308/1478708051432
27. Ali L, Khan S, Khan FH, Orakzai N (2020) Comparison of percutaneous nephrostomy and double J stent in early normalization of renal function tests in patients with obstructive uropathy due to urolithiasis. Ann Pak Inst Med Sci 16:10–14. https://doi.org/10.48036/apims.v16i1.301
28. Ahmad I, Saeed Pansota M, Tariq M, Shahzad Saleem M, Ali Tabassum S, Hussain A (2013) Comparison between Double J (DJ) Ureteral stenting and percutaneous nephrostomy (PCN) in obstructive uropathy. Pak J Med Sci 29:725–729. https://doi.org/10.12669/pjms.293.3563
29. Ekici S, Sahin A, Ozen H (2001) Percutaneous nephrostomy in the management of malignant ureteral obstruction secondary to bladder cancer. J Endourol 15:827–829. https://doi.org/10.1089/089277901753205834
30. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064. https://doi.org/10.1097/01.ju.0000049198.53424.1d

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.